Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed the approval of Verastem Oncology’s COPIKTRA™ (duvelisib) capsules by the U.S. Food and Drug Administration (FDA). COPIKTRA is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.
(PRWeb October 16, 2018)
Read the full story at https://www.prweb.com/releases/catalent_and_verastem_oncology_partner_on_newly_launched_fda_approved_copiktra_duvelisib_capsules/prweb15844172.htm